Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX-10726 in Advanced Malignancies
NCT07419841Phase 1Recruiting
- Sponsor
- Compass Therapeutics, Inc.
- Start
- May 2026
- Primary completion
- Apr 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CTX-10726 in gastroesophageal junction cancer, hepatocellular carcinoma (HCC), endometrial cancer (EC) and 1 more (2 cohorts), sponsored by Compass Therapeutics, Inc. Primary endpoints: Treatment-Emergent Adverse Events up to 2 years and Determine the dose(s) of CTX-10726 to be further examined at 6 months. Started May 2026; status: recruiting.
02
Drugs
CTX-10726
03
Conditions
gastroesophageal junction cancerhepatocellular carcinoma (HCC)endometrial cancer (EC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07419841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07419841.